Detection kit and detection method for multiple mutations of human PIK3CA gene
Through real-time fluorescence PCR combined with ARMS-PCR technology, the problems of low efficiency, easy pollution and poor accuracy of PIK3CA gene mutation detection in the existing technology are solved, and fast, accurate and specific detection is achieved, with high detection sensitivity and avoiding false positives. As a result, it is suitable for clinical applications.
Patent Information
- Application Number
- CN202410528020.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-29
- Publication Date
- 2024-11-12
AI Technical Summary
The existing PIK3CA gene mutation detection methods have problems such as low detection efficiency, easy sample contamination, long detection time and poor accuracy. In particular, the false positive rate of real-time fluorescence quantitative detection technology is high, which affects the specificity of the detection results.
Using real-time fluorescent PCR combined with ARMS-PCR technology, amplification is performed on mutant DNA only by designing specific primers and Taq Man probes, preventing the amplification of wild-type DNA, improving the specificity and sensitivity of the detection, and through internal control Monitoring reduces false negative results.
It realizes rapid, accurate and specific mutation detection of multiple genes of PIK3CA, with a detection sensitivity of 0.02%, avoiding false positive results of wild type misamplification by mutation primers. It is simple to operate, low cost, and is suitable for clinical applications.
Smart Images

Figure CN118932050A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of nucleic acid detection, and in particular, relates to a detection kit and a detection method for multiple mutations of the human PIK3CA gene. Background Art
[0002] PIK3CA (Phosphatidylinositol 3-kinase catalyticalpha) gene is an oncogene detected by Volinia et al. in 1994. It is a lipid kinase encoding gene and is the homolog of the retroviral V-P3K oncogene in cells. PIK3CA is a 34kb gene on chromosome 3q26.3, which consists of 20 exons encoding 1068 amino acids. This group of amino acids produces a group of 124KD proteins, namely the p110 catalytic subunit of class I phosphatidylinositol-3-kinase (PI3Ks), namely PI3Kp110a.
[0003] PIK3CA is an important kinase molecule located in the downstream cascade signaling pathway of epidermal growth factor receptor (EGFR), and plays the role of proto-oncogene in the occurrence of tumors. Studies have found that about 80% of PIK3CA gene mutations in human tumors are in the helical region and kinase region, namely exons 9 and 20. PIK3CA gene mutations cause abnormal activation of p110a. In addition, the Ras protein bound to GTP directly binds to p110a. At the same time, growth factor receptors with phosphorylated tyrosine residues, connexins, and PI3Ks regulatory subunit p85 are also involved. Together, they overactivate PI3Ks through a complex mechanism. Activated PI3Ks further activate downstream signaling molecules such as Akt. Activated Akt activates or inhibits its downstream proteins through phosphorylation to regulate cell proliferation, differentiation, apoptosis, and migration, ultimately leading to the occurrence of tumors. As a key component of the PI3K-AKT-mTOR signaling pathway, PIK3CA regulates tumor cell proliferation, differentiation, apoptosis, and angiogenesis. PIK3CA gene is a common mutation gene found in colon cancer, liver cancer and breast cancer in recent years, in addition to p53 mutation and HER-2 amplification. Its mutation sites are concentrated in exon 9 and exon 20. The five most common mutation hotspots are: E542K, E545K, E545D and H1047R / L, among which the mutation frequency of E542K is 5.7%, the mutation frequency of E545K is 8.5%, the mutation frequency of E545D is 0.2%, and the mutation frequency of H1047R / L is 18.8%. Studies have found that trastuzumab has poor efficacy in people with PIK3CA gene mutations in the PIK3-AKT (phosphatidylinositol-3 kinase / serine-threonine protein kinase B) pathway; other studies have shown that colorectal cancer patients with PIK3CA gene mutations are resistant to cetuximab; in addition, 2% of lung cancer patients are accompanied by PIK3CA mutations, and patients with mutations are associated with TKI drug resistance. In recent years, a new research target has emerged in the treatment of colorectal cancer, the PIK3CA gene. Studies have found that the mutation rate of the PIK3CA gene in colorectal cancer is significantly lower than that of foreign results. The reason may be that the PIK3CA gene mutation is related to differences in race and regional environment, and the mutation sites of this gene are different between different races and regions. Although further research is needed on the impact of PIK3CA mutation on colorectal cancer, it can be seen from the existing research that the discovery of PIK3CA high-frequency mutations and mutation hotspots still has certain clinical significance for the genetic diagnosis and targeted treatment of colorectal cancer.
[0004] PI3K is a type of specific phosphorylation of inositol phospholipid 3-hydroxy kinase, known as the PI3Ks family. Class I PI3Ks is a heterodimer composed of a p110 catalytic subunit and a p85 regulatory subunit, which is activated by growth factor receptors and insulin receptors. PI3Ks are usually expressed in the cytoplasm and produce inositol lipid substances with second messenger functions, which play a very important role in the regulation of cell morphology, vitality, invasiveness, apoptosis and cell cycle. The PI3K-Akt signaling pathway is an important signaling pathway for regulating cell function. When the PIK3CA gene is activated in the form of gene amplification or point mutation, its transcription and translation levels increase, and AKT is overactivated through the PI3K / AKT pathway, which promotes cell growth and reproduction without restraint, and inhibits cell apoptosis, which will eventually lead to the occurrence of tumors. Mutations in this gene can occur in breast cancer, colorectal cancer, lung cancer and other cancers, with a mutation rate of 26% in breast cancer, 25% in colorectal cancer and 2% in lung cancer. The mutation status of the PIK3CA gene directly or indirectly affects the medication and prognosis of colorectal cancer, breast cancer, lung cancer and other cancers. Targeted therapeutic drugs for colorectal cancer are anti-EGFR monoclonal antibodies, such as cetuximab and panitumumab, which can block the conduction of EGFR downstream signaling pathways, thereby exerting an anti-tumor effect.
[0005] Although the use of gene sequencing technology to detect colorectal cancer mutations is the most direct, due to cost considerations, there are currently some PCR-based detection technologies to detect mutations in colorectal cancer-related mutant genes such as PIK3CA. For example, Chinese Patent CN201110344347 discloses primers, probes and kits for human PIK3CA gene-driven mutations, which involve the detection of gene mutations. Chinese Patent No. CN201210234133 discloses a kit for detecting hotspot mutation sites of the PIK3CA gene in colorectal cancer. Chinese Patent No. CN201510213332 discloses a kit for detecting PIK3CA gene mutations and a detection method thereof, the kit containing an LNA locked nucleic acid modified specific probe for the PIK3CA gene mutation site. Chinese Patent No. CN202010297730 discloses a kit suitable for dPCR to detect PIK3CA gene mutations. Chinese Patent No. CN202211089987 discloses a kit and method for detecting PIK3CA gene mutations. The methods used in the above patents include driver mutation fluorescence PCR, pyrophosphate sequencing technology, dPCR, sequencing analysis and enrichment analysis methods. The above technologies may have primers for detecting mutations that easily detect wild-type PIK3CA, which will affect the interpretation of the results and cause false positives. The most advanced technology for detecting PIK3CA gene mutations in the world is site-specific fluorescence quantitative PCR. The advantage of this method is that it improves the detection sensitivity and timeliness of the detection, but the real-time fluorescence quantitative detection technology itself has the problem of high false positive rate, that is, poor specificity.
[0006] In summary, in view of the deficiencies of the existing technology and actual needs, a kit for detecting multiple PIK3CA gene mutations that is simple to operate, highly specific, rapid and accurate is needed to solve the above problems. Summary of the invention
[0007] The purpose of the present invention is to solve the problems of low detection efficiency, easy sample contamination, long detection time, poor accuracy, etc. of the existing PIK3CA gene mutation detection method, and provide a detection kit and detection method for multiple mutations of the human PIK3CA gene, so as to achieve rapid and accurate detection in any place, simple operation and strong specificity.
[0008] To achieve the above object, the present invention provides the following technical solution: a human PIK3CA gene mutation detection kit, comprising:
[0009] (1) an internal reference detection reagent, which comprises an internal standard specific primer, an internal standard specific probe and a dNTP solution;
[0010] (2) PIK3CA mutation detection reagent, which includes PIK3CA gene mutation-specific primers, mutation-specific primer probes and Mg 2+ Aqueous solution;
[0011] (3) Taq DNA polymerase, PIK3CA negative control and positive control, which contain fragments of wild-type and mutant forms and an internal standard gene, respectively;
[0012] Wherein, the PIK3CA gene mutation type in the PIK3CA mutation detection reagent is selected from:
[0013] Mutation Name Base mutation form Amino acid mutation form Exon B1(E542K) GAA>AAA Glu542Lys 9 B2(E545K) GAG>AAG Glu545Lys 9 B3(E545D) GAG>GAT Glu545Asp 9 B4(H1047R) CAT>CGT His1047Arg 20 B5(H1047L) CAT>CTT His1047Leu 20
[0014] The relevant primer and probe nucleotide sequences are as follows:
[0015] IC: Internal standard specificity
[0016] Internal standard upstream primer IL: ATGGGAAACAGACGAATGC
[0017] Internal standard downstream primer IR: ACAGCAAATAAAAGAAACTAAAACA Internal standard probe IP: TCCTGAGACTTCCACACTGATGC B1: E542K mutation
[0018] Mutant upstream primer M1L: CTACACGAGATCCTCTCTGCA Mutant downstream primer M1R: GAGATCAGCCAAATTCAGTTACT Mutant probe M1P: ATGGAGTCACAGGTAAGTGCTAAAATGG B2: E545K mutation Mutant upstream primer M2L: CGAGATCCTCTCTCTGAAATTACTA Mutant downstream primer M2R: GAGATCAGCCAAATTCAGTTAGT Mutant probe M2P: ATGGAGTCACAGGTAAGTGCTAAAATGG B3: E545D mutation
[0019] Mutant upstream primer M3L: GATCCTCTCTCTGAAATCACTCGT Mutant downstream primer M3R: GAGATCAGCCAAATTCAGTTACT Mutant probe M3P: ATGGAGTCACAGGTAAGTGCTAAAATGG B4: H1047R mutation
[0020] Mutant upstream primer M4L: ATGAAACAAATGAATGATGCATG Mutant downstream primer M4R: CAGAGTGAGCTTTCATTTTGT Mutant probe M4P: TGGCTGGACAACAAAAATGGATTGG B5: H1047L mutation
[0021] Mutant upstream primer M5L: CATGAAACAAATGAATGATGCTAT
[0022] Mutant downstream primer M5R: CAGAGTGAGCTTTCATTTTGT
[0023] Mutant probe M5P: TGGCTGGACAACAAAAATGGATTGG B6: wild type
[0024] Wild-type upstream primer WL: AGCTCAAAGCAATTTCTACACGT
[0025] Wild-type downstream primer WR: GAGATCAGCCAAATTCAGTTACT
[0026] Wild-type probe WP: ATGGAGTCACAGGTAAGTGCTAAAATGG.
[0027] It further includes DNA polymerase and uracil DNA glycosylase with anti-pollution effect. A method for detecting human PIK3CA gene mutation includes the following steps:
[0028] (1) extracting nucleic acid from a sample to obtain a nucleic acid extract;
[0029] (2) A fluorescent PCR amplification reaction system was prepared by mixing a nucleic acid extract, a DNA polymerase, dNTPs, primers and probes in six PCR reaction tubes, respectively. The nucleotide sequences of the primers and probes contained in each reaction tube were shown in the following table:
[0030] Tube No. Primers Probe 1 IL, IR, M1L, M1R M1P 2 IL, IR, M2L, M2R M2P 3 IL, IR, M3L, M3R M3P 4 IL, IR, M4L, M4R M4P 5 IL, IR, M5L, M5R M5P 6 IL, IR, WL, WR WP
[0031] Wherein, the PIK3CA gene mutation type in the PIK3CA mutation detection reagent is selected from:
[0032]
[0033]
[0034] The relevant primer and probe nucleotide sequences are as follows:
[0035] IC: Internal standard specificity
[0036] Internal standard upstream primer IL: ATGGGAAACAGACGAATGC
[0037] Internal standard downstream primer IR: ACAGCAAATAAAAGAAACTAAAACA Internal standard probe IP: TCCTGAGACTTCCACACTGATGC B1: E542K mutation
[0038] Mutant upstream primer M1L: CTACACGAGATCCTCTCTGCA Mutant downstream primer M1R: GAGATCAGCCAAATTCAGTTACT Mutant probe M1P: ATGGAGTCACAGGTAAGTGCTAAAATGG B2: E545K mutation Mutant upstream primer M2L: CGAGATCCTCTCTCTGAAATTACTA Mutant downstream primer M2R: GAGATCAGCCAAATTCAGTTAGT Mutant probe M2P: ATGGAGTCACAGGTAAGTGCTAAAATGG B3: E545D mutation
[0039] Mutant upstream primer M3L: GATCCTCTCTCTGAAATCACTCGT Mutant downstream primer M3R: GAGATCAGCCAAATTCAGTTACT Mutant probe M3P: ATGGAGTCACAGGTAAGTGCTAAAATGG B4: H1047R mutation
[0040] Mutant upstream primer M4L: ATGAAACAAATGAATGATGCATG
[0041] Mutant downstream primer M4R: CAGAGTGAGCTTTCATTTTGT
[0042] Mutation probe M4P: TGGCTGGACAACAAAAATGGATTGG B5: H1047L mutation
[0043] Mutant upstream primer M5L: CATGAAACAAATGAATGATGCTAT
[0044] Mutant downstream primer M5R: CAGAGTGAGCTTTCATTTTGT
[0045] Mutant probe M5P: TGGCTGGACAACAAAAATGGATTGG B6: wild type
[0046] Wild-type upstream primer WL: AGCTCAAAGCAATTTCTACACGT
[0047] Wild-type downstream primer WR: GAGATCAGCCAAATTCAGTTACT
[0048] Wild-type probe WP: ATGGAGTCACAGGTAAGTGCTAAAATGG
[0049] (3) adding the nucleic acid extract to the mutant reaction system and the wild-type reaction system respectively to perform fluorescence quantitative PCR reaction;
[0050] (4) Analyze the detection results based on the difference in Ct values of FAM signals between the mutant reaction system and the wild-type reaction system.
[0051] The nucleic acid extract is extracted from the sample by magnetic bead extraction method, and the extraction process is: add nucleic acid extract to the sample, add magnetic beads after heat preservation, mix evenly, apply magnetic field, discard the liquid, wash and elute.
[0052] Each reaction tube further comprises an internal control nucleic acid, an internal control primer and an internal control probe.
[0053] The PCR reaction conditions are:
[0054] 50℃ 2 minutes 94℃ 5 minutes
[0055] 94℃ 10 seconds 55℃ 45 seconds × 40 cycles
[0056] The fluorescent group is FAM, the fluorescent group of the internal standard primer probe is VIC / HEX, and all the probes are marked with fluorescent groups and quenching groups.
[0057] The reagents required for the magnetic bead extraction method include:
[0058] A nucleic acid extraction solution comprising guanidine isothiocyanate, sodium ethylenediaminetetraacetate, Tween-20, sodium perchlorate, ethanol and pH buffer;
[0059] a washing solution used in the first washing, which comprises sodium perchlorate and ethanol;
[0060] The second wash uses a wash solution comprising ethanol and a pH buffer.
[0061] Compared with the prior art, the present invention has the following benefits: The present invention uses real-time fluorescence PCR combined with ARMS-PCR, which is called amplification refractory mutation system (ARMS), also known as allele-specific PCR (AS-PCR), etc., to detect known mutant genes. The method designs two 5'-end primers, one complementary to normal DNA and the other complementary to mutant DNA. For homozygous mutations, these two primers and 3'-end primers are added respectively to perform two parallel PCRs. Only primers that are completely complementary to mutant DNA can be extended to obtain PCR amplification products. If the mismatch is located at the 3' end of the primer, the PCR cannot be extended. ARMS-PCR is a commonly used gene mutation detection method in laboratories. The ARMS-PCR method has high detection sensitivity and can detect mutant genes with a mutation ratio of 1% or even lower in tumor cells.
[0062] Compared with existing detection kits, the real-time fluorescence PCR method is used to detect the PIK3CA mutant gene in DNA samples by combining specific primers and Taq Man probe technology. The mutant target sequence is amplified using specific primers, while the amplification of the wild type is blocked. The amplified product is detected by Taq Man probe, so that the mutant gene is amplified while the wild type is basically not amplified, thereby achieving high detection specificity and high sensitivity.
[0063] The present invention combines ARMS-PCR technology to make the primers designed with mutant bases only amplify the corresponding mutant templates, and introduce mismatched bases at the 3' end of the primers to form mismatches with the template to prevent erroneous extension. The specificity level of the system is further improved, thereby achieving the detection of low-content mutant sequences in a high wild-type gene background;
[0064] 2. Compared with the prior art, the present invention introduces ARMS-PCR technology, which is simple to operate, has low detection cost and accurate detection results, and has good clinical application value and market value;
[0065] 3. It is possible to detect the presence of five human PIK3CA mutant genes in samples using only a small number of PCR tubes in one round of PCR, ensuring accuracy, reliability, specificity, sensitivity and repeatability, especially avoiding the generation of false positive results caused by mistaken amplification of wild-type PIK3CA by mutant primers; and it uses currently available commercial real-time fluorescence PCR equipment without the need for modification, is easy to operate and saves costs, and can use internal control monitoring to further control false negatives.
[0066] 4. The present invention establishes a real-time fluorescence PCR amplification reaction system to achieve rapid detection of PIK3CA gene mutations; the operation is simple and the results are easy to read. The VIC / HEX signal Ct value reflects the relevant information of the real-time fluorescence PCR amplification reaction system (whether the sample nucleic acid extraction is normal, whether the operation process is accurate, etc.);
[0067] 5. The detection sensitivity reaches 0.02%, and the detection process is a closed tube reaction to reduce the possibility of contamination;
[0068] 6. Good safety. The entire system does not contain toxic or hazardous substances and is harmless to experimenters and the environment.
[0069] For ease of understanding, the present invention will be described in detail below through specific drawings and embodiments. It should be particularly pointed out that these descriptions are merely exemplary descriptions and do not constitute a limitation on the scope of the present invention. According to the discussion of this specification, many changes and modifications of the present invention are obvious to those skilled in the art. In addition, the present invention quotes public documents, which are intended to more clearly describe the present invention, and their full texts are incorporated herein by reference, as if their full texts have been repeated herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] Figure 1 The schematic diagram of the qPCR results for detecting the wild-type nucleic acid control of the PIK3CA gene is shown, where lines 1 and 2 are internal controls IC, and line 3 is the external control CtW. The result curve can be clearly distinguished, but it has reached the limit.
[0071] Figure 2 The schematic diagram shows the qPCR results for detecting any positive mutation site of the five mutations of the PIK3CA gene, where line 1 is the internal control IC, line 2 is CtM, and line 3 is the external control CtW. The result curve can be clearly distinguished, but it has reached the limit.
[0072] Figure 3 The schematic diagram of the qPCR results for detecting five positive mutation sites of the PIK3CA gene is shown, where line 1 is the internal control IC, line 2 is CtM, and line 3 is the external control CtW. The result curve can be clearly distinguished, but it has reached the limit. DETAILED DESCRIPTION
[0073] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0074] The invention will be described below by way of specific embodiments.
[0075] Example 1 Extraction of nucleic acid
[0076] The test samples containing the wild-type and mutant genes of human PIK3CA of the present invention can be purchased from the National Health Ministry Clinical Inspection Center, and are all standard products for nucleic acid extraction.
[0077] The nucleic acid was extracted according to the conventional magnetic bead extraction method. In order to adapt to the extraction of nucleic acid of a large number of human PIK3CA gene mutants at the same time, the steps are as follows:
[0078] Add 90uL of nucleic acid extraction solution (formula and final concentration: 1.5M guanidine thiocyanate, 15mM sodium ethylenediaminetetraacetate (pH8.0), 3% (W / W) Tween-20, 1M sodium perchlorate, 50% (V / V) ethanol, 10mM Tris-HCl (pH8.0)) to 1uL of standard and keep at 42°C for 10min.
[0079] Then add 10uL D-Beads DNA magnetic bead suspension (50 mg / mL, available commercially) was shaken and mixed evenly, then placed on a magnetic rack to apply a magnetic field and the liquid was discarded;
[0080] Then add 200uL of washing solution A (formula and final concentration: sodium perchlorate 1.5M, ethanol 50% (V / V)), discard washing solution A after washing,
[0081] Then add 200uL of washing solution B (formula and final concentration: 70% ethanol (V / V)), and discard washing solution B after washing.
[0082] Finally, add the elution solution (formula and final concentration: Tris-HCl (pH 8.0) 10 mM), keep warm at 60°C for 10 min, aspirate and retain the liquid, which is the nucleic acid extraction solution.
[0083] Example 2 Human PIK3CA Real-time PCR Test
[0084] 1. Primer and probe sequences and fluorescent labeling
[0085] The above-mentioned nucleotide sequence primers and probes were synthesized by commission.
[0086] The 5' end of the probes of wild-type and mutant nucleotide sequences such as M1P, M2P, M3P, M4P, M5P, and WP were respectively commissioned to be synthesized and labeled with fluorescent marker FAM, and the 3' end was labeled with quenching group BHQ; the 5' end of the probe of the internal standard nucleotide sequence such as IP was commissioned to be synthesized and labeled with fluorescent marker VIC, and the 3' end was labeled with quenching group BHQ; other nucleic acids or parts were not labeled.
[0087] 2. PCR reaction grouping
[0088] Take a total of 6 PCR reaction tubes, containing the corresponding primers and probes according to the following table:
[0089]
[0090] 3. PCR Reaction Conditions
[0091] The total volume of the PCR reaction system is 25 μL, in which the final concentrations of the components are: 15 uL of nucleic acid extract (100-fold dilution); 2.0 pmol / μL of internal standard primers, and 0.75 pmol / μL of internal standard probes; 1.5 pmol / μL of mutation primers, and 1.0 pmol / μL of mutation probes; 2.0 pmol / μL of control primers, and 0.75 pmol / μL of mutation probes; 35 mmol of Mg2+ (MgCl2), 10.0 mmol of Tris-HCl (pH 8.0), 1.0 mmol of dNTPs, 0.2 M of UNG enzyme, 2.5 M of Taq DNA polymerase, 15% (V / V) of glycerol, and the remainder of deionized water.
[0092] The reaction thermal cycle conditions are as follows:
[0093]
[0094]
[0095] ABI 7500 real-time fluorescence PCR instrument was used, with FAM and VIC detection wavelengths used for fluorescence collection.
[0096] 4. Result judgment
[0097] The baseline and threshold values are set as the default automatic settings of the ABI 7500 fluorescence instrument. According to the determination method shown in the third aspect, the detection result of the sample to be tested is determined.
[0098] Exemplary test results are as follows Figure 1-3 As shown. The above test was repeated 100 times with samples containing different mutations and wild-type PIK3CA, and the results were all correct, indicating that the accuracy and reliability of the present invention are good. The method of the present invention can detect 1% multi-site mutations in 2ng / μL human genomic nucleic acid, and there is no mutual interference in the detection to produce false negative results, especially in the mutation detection, the wild type is well controlled, and there is no false positive result of wild-type PIK3CA, achieving ultra-sensitive detection sensitivity.
[0099] Specifically, in the first aspect, the present invention provides five mutant reaction solutions for simultaneously detecting five PIK3CA gene mutations, and also provides one wild-type reaction solution, and analyzes the detection results based on the difference in Ct values of the mutant reaction system and the wild-type reaction system, i.e., the external control FAM signal.
[0100] A kit for detecting hotspot mutation sites of the PIK3CA gene in colorectal cancer, comprising a PCR amplification reaction solution and a yin-yang quality control product, characterized in that the kit comprises upstream and downstream primers and probes for detecting mutation genes of exon 9 E542K, E545K, and E545D and upstream and downstream primers and probes for mutation genes of exon 20 H1047R and H1047L, as well as upstream and downstream primers and probes for internal standards and wild-type genes, and the sequences thereof are:
[0101] IC: internal standard internal standard upstream primer IL: ATGGGAAACAGACGAATGC
[0102] Internal standard downstream primer IR: ACAGCAAATAAAAGAAACTAAAACA Internal standard probe IP: TCCTGAGACTTCCACACTGATGC B1: E542K mutation
[0103] Mutant upstream primer M1L: CTACACGAGATCCTCTCTGCA Mutant downstream primer M1R: GAGATCAGCCAAATTCAGTTACT Mutant probe M1P: ATGGAGTCACAGGTAAGTGCTAAAATGG B2: E545K mutation Mutant upstream primer M2L: CGAGATCCTCTCTCTGAAATTACTA Mutant downstream primer M2R: GAGATCAGCCAAATTCAGTTAGT Mutant probe M2P: ATGGAGTCACAGGTAAGTGCTAAAATGG B3: E545D mutation
[0104] Mutant upstream primer M3L: GATCCTCTCTCTGAAATCACTCGT Mutant downstream primer M3R: GAGATCAGCCAAATTCAGTTACT Mutant probe M3P: ATGGAGTCACAGGTAAGTGCTAAAATGG B4: H1047R mutation
[0105] Mutant upstream primer M4L: ATGAAACAAATGAATGATGCATG Mutant downstream primer M4R: CAGAGTGAGCTTTCATTTTGT Mutant probe M4P: TGGCTGGACAACAAAAATGGATTGG B5: H1047L mutation
[0106] Mutant upstream primer M5L: CATGAAACAAATGAATGATGCTAT Mutant downstream primer M5R: CAGAGTGAGCTTTCATTTTGT Mutant probe M5P: TGGCTGGACAACAAAAATGGATTGG B6: wild type
[0107] Wild-type upstream primer WL: AGCTCAAAGCAATTTCTACACGT
[0108] Wild-type downstream primer WR: GAGATCAGCCAAATTCAGTTACT
[0109] Wild-type probe WP: ATGGAGTCACAGGTAAGTGCTAAAATGG
[0110] The primers in the above technical solution are reasonably designed to amplify only the part containing E542K, E545K / D and H1047R / L codons of the PIK3CA gene. The specific primers of the present invention are one of the inventive points of the present invention, and the primers can be prepared by conventional methods for preparing primers by those skilled in the art. When the primers are prepared according to the present invention, a suitable assay sample can be obtained, which is used as an amplified DNA fragment and has a specific length.
[0111] Preferably, the PCR reaction solution comprises DNA polymerase, dNTP, PCR reaction buffer and water.
[0112] Preferably, the DNA polymerase can be Taq DNA polymerase.
[0113] In a second aspect, as a preferred technical solution, the method for detecting PIK3CA gene mutation for the purpose of non-disease diagnosis and / or treatment comprises:
[0114] (1) Collect the genomic DNA to be analyzed according to routine procedures, and the test samples are paraffin-embedded sections (preferably, extracted using the magnetic bead method).
[0115] (2) A real-time fluorescent PCR amplification system was prepared by mixing a nucleic acid extract, a DNA polymerase, dNTPs, primers and probes in six PCR reaction tubes, respectively. The nucleotide sequences of the primers and probes contained in each reaction tube were shown in the following table:
[0116]
[0117]
[0118] In addition to these 6 PCR tubes, other PCR tubes may be included, such as negative control tubes in which the nucleic acid extract is replaced with water; or positive control tubes in which the nucleic acid extract is replaced with a sample known to contain mutant or wild-type PIK3CA.
[0119] In this article, the term "number" is used to distinguish multiple objects of the same category (i.e., to indicate that objects assigned different numbers are different) and can be used to refer to and reference, rather than a specific number. A specific number can be remapped to other numbering methods in a one-to-one correspondence manner.
[0120] The nucleic acid extract can be directly tested, but it is preferred to process the sample to obtain the nucleic acid extract before testing. Therefore, it is preferred that the nucleic acid extract is an extract obtained by extracting nucleic acids from the sample, such as by using a magnetic bead extraction method. The non-specific magnetic bead extraction method uses paramagnetic particles coated with non-specific nucleic acid adsorption substances. Under low pH (e.g., pH 5-7) and high salt concentration conditions, nucleic acids can be adsorbed to the surface of the paramagnetic particles. After magnetic separation and sufficient washing, the nucleic acids can be eluted under high pH (e.g., pH 8-9) and low salt concentration conditions. The sample enriched with nucleic acids (e.g., target nucleic acids) can be used for PCR tests; in addition, a magnetic bead extraction method with specific adsorption (e.g., hybridization adsorption and immunoadsorption) can also be used. These processing procedures are well known to those skilled in the art, and can also be found in Zheng Xiufen et al., Template DNA Magnetic Bead Extraction Method. Chinese Journal of Forensic Medicine, 18(3): 107-108; Chinese Patents 200610030229.5, 200710118802.2 and 201110105181.0, etc.
[0121] Preferably, the magnetic bead extraction method further optimized in the present invention is more reliable and convenient for extracting nucleic acids from human tissue samples.
[0122] The process of extracting nucleic acid from the test sample is: adding a nucleic acid extraction solution to the sample (preferably the nucleic acid extraction solution contains guanidine isothiocyanate, sodium ethylenediaminetetraacetic acid, Tween-20, sodium perchlorate, ethanol and pH buffer (such as Tris-HCl)), adding magnetic beads after incubation, mixing evenly, applying a magnetic field, discarding the liquid, and then washing (preferably washing twice, more preferably wherein the washing solution used for the first wash contains sodium perchlorate and ethanol, and more preferably wherein the washing solution used for the second wash contains ethanol), and eluting (preferably the elution solution used for elution contains pH buffer (such as Tris-HCl)).
[0123] Therefore, in the method of the first aspect of the present invention, the nucleic acid extract is extracted from the sample, for example, wherein the extraction is extracted by magnetic bead extraction. That is, preferably the method of the first aspect of the present invention includes the step of extracting nucleic acid from the sample to obtain the nucleic acid extract.
[0124] (3) The above genomic DNA is added to each detection reaction system and quality control reaction system respectively, and a fluorescence quantitative PCR reaction is performed; in addition, a yin-yang control corresponding to each mutation is set, and the same operation is performed with the genomic DNA of the sample to be tested, and the test results are analyzed according to the Ct value to determine whether the sample to be tested has a mutation. The real-time fluorescence quantitative PCR instrument of the present invention collects fluorescence signals simultaneously during the PCR amplification process according to the set requirements. The multi-channel fluorescence instrument collects multi-signal fluorescence according to the pre-set, and the fluorescence channels collected are FAM and VIC / HEX. The kit adds an internal standard system to the amplification detection system to monitor the entire process from nucleic acid extraction to amplification detection.
[0125] In the real-time fluorescence PCR reaction, the Ct value represents the number of cycles experienced when the fluorescent signal in each PCR reaction tube reaches the threshold value set by default by the real-time fluorescence PCR instrument. It has good reproducibility and can therefore be used as an excellent indicator for interpreting the results. In the method of the first aspect of the present invention, for step (3), if the Ct value calculated from the fluorescence detection result of one target nucleic acid is <40, then the target nucleic acid is present in the sample; if the Ct value calculated from the fluorescence detection result of one target nucleic acid is >40, then the target nucleic acid is not present in the sample. This is our experience gained through long-term and extensive experiments, with excellent reliability and repeatability. Therefore, in the method of the first aspect of the present invention, an internal control is also preferably used. The internal control comprises an internal control nucleic acid, an internal control primer, and an internal control probe.
[0126] (4) The amplification system in the above step is 25 μL, including 10 μL of amplification reaction solution and 15 μL of genomic DNA of the sample to be tested. Since the concentration of the probe is increased, the detection sensitivity of the method of the first aspect of the present invention can be further improved. Therefore, preferably, in the method of the first aspect of the present invention, the concentration of each target nucleic acid probe in the single PCR reaction tube is greater than 5 pmol / ml, preferably 6 to 12 pmol / ml, more preferably 7 to 10 pmol / ml, and most preferably 8 pmol / ml.
[0127] In addition, other reagents required for the PCR reaction, such as salts, are further mixed in the single PCR reaction tube described in step (1). The glycerol concentration is also optimized to prolong the enzyme activity durability under PCR conditions. In a specific embodiment of the present invention, the salt is preferably a Mg salt. Those skilled in the art can also easily select other pH buffers (such as phosphate buffer, etc.) to adjust to a suitable pH, and can also easily select other soluble salts (such as KCl, etc.) to adjust the ionic strength. In addition, antioxidants (reducing agents), protein (enzyme) protective agents (such as bovine serum albumin (BSA), human serum albumin (HSA), etc.) can also be further mixed. The selection of these ingredients is well known to those skilled in the art.
[0128] Those skilled in the art can design PCR reaction conditions according to the primers and the corresponding nucleic acid to be amplified by PCR. In the detection of the present invention, in order to balance the amplification conditions of different mutants, the inventors have optimized the conditions after long-term exploration as follows:
[0129]
[0130]
[0131] The test results are analyzed based on the difference in Ct values between the mutant reaction system and the wild-type reaction system, i.e., the external control FAM signal. First, the negative control FAM signal does not produce a line or the Ct value is greater than 40 and the internal standard, i.e., the VIC / HEX signal, satisfies the Ct value ≤30, the positive control FAM signal value Ct value ≤30, and the internal standard, i.e., the VIC / HEX signal Ct value ≤30 or does not produce a line. As for how to determine whether the sample to be tested is a mutant, it is first necessary to satisfy the internal standard, i.e., the VIC / HEX signal Ct value ≤30, the FAM signal Ct value obtained by the mutant reaction system is defined as CtM, and the wild-type reaction solution system, i.e., the external control FAM signal Ct value is defined as CtW, and then the difference in Ct values between the mutant reaction system and the wild-type reaction system FAM signal ΔCt = CtM-CtW is used for determination:
[0132] The difference of FAM signal Ct value between the detection reaction system containing primers and probes of PIK3CA: E542K (c.1624G>A) mutation and the external control reaction system is >10 for wild type, and less than or equal to 10 for E542K (c.1624G>A) mutation;
[0133] The difference in FAM signal Ct value between the detection reaction system containing primers and probes for PIK3CA: E545K (c.1633G>A) mutation and the external control reaction system is >10 for wild type, and less than or equal to 10 for E545K (c.1633G>A) mutation;
[0134] The difference in FAM signal Ct value between the detection reaction system containing primers and probes for PIK3CA: E545D (c.1635G>T) mutation and the external control reaction system is >10 for wild type, and less than or equal to 10 for E545D (c.1635G>T) mutation;
[0135] The difference of FAM signal Ct value between the detection reaction system containing primers and probes of PIK3CA: H1047R (c.3140A>G) mutation and the external control reaction system is >10 for wild type, and less than or equal to 10 for H1047R (c.3140A>G) mutation;
[0136] If the difference in FAM signal Ct value between the detection reaction system containing primers and probes of PIK3CA: H1047L (c.3140A>T) mutation and the external control reaction system is >10, it indicates wild type; if it is less than or equal to 10, it indicates E545D H1047R (c.3140G>A) mutation type.
[0137] The kit of the second aspect of the present invention may further include reagents required for the magnetic bead extraction method, preferably wherein the reagents required for the magnetic bead extraction method include:
[0138] A nucleic acid extraction solution, preferably a nucleic acid extraction solution comprising guanidine isothiocyanate, sodium ethylenediaminetetraacetate, Tween-20, sodium perchlorate, ethanol and a pH buffer (e.g., Tris-HCl);
[0139] The washing liquid used for the first washing preferably comprises sodium perchlorate and ethanol;
[0140] The washing solution used in the second washing preferably contains ethanol; and the elution solution used in the elution preferably contains a pH buffer solution (eg, Tris-HCl).
[0141] It is also preferred that the kit of the second aspect of the present invention further comprises a reagent container for further testing of the nucleic acid extract, and more preferably a reagent container for real-time PCR testing.
[0142] In a third aspect, the present invention provides the use of the kit described in the second aspect of the present invention in the preparation of a detection reagent product for a detection method for human PIK3CA gene mutation. In this article, the detection reagent product can be the detection kit itself, or it can be a larger packaged product combined with multiple detection kits. According to the foregoing, it is easy for those skilled in the art to understand the composition of the detection kit and the process of the method.
Claims
1. A human PIK3CA gene mutation detection kit, characterized in that: It contains: (1) an internal reference detection reagent, which comprises an internal standard specific primer, an internal standard specific probe and a dNTP solution; (2) PIK3CA mutation detection reagent, which includes PIK3CA gene mutation-specific primers, mutation-specific primer probes and Mg 2+ Aqueous solution; (3) Taq DNA polymerase, PIK3CA negative control and positive control, which contain fragments of wild-type and mutant forms and an internal standard gene, respectively; Wherein, the PIK3CA gene mutation type in the PIK3CA mutation detection reagent is selected from: The relevant primer and probe nucleotide sequences are as follows: IC: Internal standard specificity Internal standard upstream primer IL: ATGGGAAACAGACGAATGC Internal standard downstream primer IR: ACAGCAAATAAAAGAAACTAAAACA Internal standard probe IP: TCCTGAGACTTCCACACTGATGC B1: E542K mutation Mutant upstream primer M1L: CTACACGAGATCCTCTCTGCA Mutant downstream primer M1R: GAGATCAGCCAAATTCAGTTACT Mutation probe M1P: ATGGAGTCACAGGTAAGTGCTAAAATGG B2: E545K mutation Mutant upstream primer M2L: CGAGATCCTCTCTCTGAAATTACTA Mutant downstream primer M2R: GAGATCAGCCAAATTCAGTTAGT Mutation probe M2P: ATGGAGTCACAGGTAAGTGCTAAAATGG B3:E545D mutation Mutant upstream primer M3L: GATCCTCTCTCTGAAATCACTCGT Mutant downstream primer M3R: GAGATCAGCCAAATTCAGTTACT Mutation probe M3P: ATGGAGTCACAGGTAAGTGCTAAAATGG B4: H1047R mutation Mutant upstream primer M4L: ATGAAACAAATGAATGATGCATG Mutant downstream primer M4R: CAGAGTGAGCTTTCATTTTGT Mutation probe M4P: TGGCTGGACAACAAAAATGGATTGG B5:H1047L mutation Mutant upstream primer M5L: CATGAAACAAATGAATGATGCTAT Mutant downstream primer M5R: CAGAGTGAGCTTTCATTTTGT Mutation probe M5P: TGGCTGGACAACAAAAATGGATTGG B6: wild type Wild-type upstream primer WL: AGCTCAAAGCAATTTCTACACGT Wild-type downstream primer WR: GAGATCAGCCAAATTCAGTTACT Wild-type probe WP: ATGGAGTCACAGGTAAGTGCTAAAATGG.
2. The human PIK3CA gene mutation detection kit according to claim 1, characterized in that: The invention further comprises DNA polymerase and uracil DNA glycosylase having anti-pollution effect.
3. A method for detecting human PIK3CA gene mutation, characterized in that: The following steps are involved: (1) extracting nucleic acid from a sample to obtain a nucleic acid extract; (2) A fluorescent PCR amplification reaction system was prepared by mixing a nucleic acid extract, a DNA polymerase, dNTPs, primers and probes in six PCR reaction tubes, respectively. The nucleotide sequences of the primers and probes contained in each reaction tube were shown in the following table: Wherein, the PIK3CA gene mutation type in the PIK3CA mutation detection reagent is selected from: The relevant primer and probe nucleotide sequences are as follows: IC: Internal standard specificity Internal standard upstream primer IL: ATGGGAAACAGACGAATGC Internal standard downstream primer IR: ACAGCAAATAAAAGAAACTAAAACA Internal standard probe IP: TCCTGAGACTTCCACACTGATGC B1: E542K mutation Mutant upstream primer M1L: CTACACGAGATCCTCTCTGCA Mutant downstream primer M1R: GAGATCAGCCAAATTCAGTTACT Mutant probe M1P: ATGGAGTCACAGGTAAGTGCTAAAATGG B2: E545K mutation Mutant upstream primer M2L: CGAGATCCTCTCTCTGAAATTACTA Mutant downstream primer M2R: GAGATCAGCCAAATTCAGTTAGT Mutant probe M2P: ATGGAGTCACAGGTAAGTGCTAAAATGG B3:E545D mutation Mutant upstream primer M3L: GATCCTCTCTCTGAAATCACTCGT Mutant downstream primer M3R: GAGATCAGCCAAATTCAGTTACT Mutant probe M3P: ATGGAGTCACAGGTAAGTGCTAAAATGG B4: H1047R mutation Mutant upstream primer M4L: ATGAAACAAATGAATGATGCATG Mutant downstream primer M4R: CAGAGTGAGCTTTCATTTTGT Mutation probe M4P: TGGCTGGACAACAAAAATGGATTGG B5:H1047L mutation Mutant upstream primer M5L: CATGAAACAAATGAATGATGCTAT Mutant downstream primer M5R: CAGAGTGAGCTTTCATTTTGT Mutation probe M5P: TGGCTGGACAACAAAAATGGATTGG B6: wild type Wild-type upstream primer WL: AGCTCAAAGCAATTTCTACACGT Wild-type downstream primer WR: GAGATCAGCCAAATTCAGTTACT Wild-type probe WP: ATGGAGTCACAGGTAAGTGCTAAAATGG (3) adding the nucleic acid extract to the mutant reaction system and the wild-type reaction system respectively to perform fluorescence quantitative PCR reaction; (4) Analyze the test results based on the difference in FAM signal Ct values between the mutant reaction system and the wild-type reaction system.
4. The method for detecting human PIK3CA gene mutation according to claim 3, characterized in that: The nucleic acid extract is extracted from the sample by magnetic bead extraction method, and the extraction process is: add nucleic acid extract to the sample, add magnetic beads after heat preservation, mix evenly, apply magnetic field, discard the liquid, wash and elute.
5. The method for detecting human PIK3CA gene mutation according to claim 4, characterized in that: Each reaction tube further comprises an internal control nucleic acid, an internal control primer and an internal control probe.
6. The method for detecting human PIK3CA gene mutation according to claim 5, characterized in that: The PCR reaction conditions are: 50℃ 2 minutes 94℃ 5 minutes 94°C 10 sec, 55°C 45 sec × 40 cycles.
7. The primers and probes for detecting five mutations in the human PIK3CA gene according to claim 1, characterized in that: The fluorescent group is FAM, the fluorescent group of the internal standard primer probe is VIC / HEX, and all the probes are marked with fluorescent groups and quenching groups.
8. The method for detecting human PIK3CA gene mutation according to claim 4, wherein the reagents required for the magnetic bead extraction method include: A nucleic acid extraction solution comprising guanidine isothiocyanate, sodium ethylenediaminetetraacetate, Tween-20, sodium perchlorate, ethanol and pH buffer; a washing solution used in the first washing, which comprises sodium perchlorate and ethanol; The second wash uses a wash solution comprising ethanol and a pH buffer.
Citation Information
Patent Citations
Reagent box and method for genome extraction on automatic nucleic acid extraction workstation
CN101323852A
Method for extracting purified DNA from human exfoliative cells
CN102181434A
Probe, primer and kit for detecting drive mutation of PIK3CA (Phosphatidylinositol-3-kinases) gene
CN102453765A
Kit for detecting hot spot mutation sites in colorectal cancer PIK3CA gene
CN102816839A
Kit for detecting PIK3CA gene mutation and detecting method thereof
CN104774963A
